MARKET

DCTH

DCTH

Delcath Systems Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

11.27
-0.09
-0.79%
Closed 16:00 10/20 EDT
OPEN
11.48
PREV CLOSE
11.36
HIGH
11.70
LOW
11.26
VOLUME
64.71K
TURNOVER
--
52 WEEK HIGH
70.00
52 WEEK LOW
0.0411
MARKET CAP
46.10M
P/E (TTM)
-0.3355
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Delcath Strengthens Executive Team with Appointment of Gerard Michel as Chief Executive Officer
GlobeNewswire · 10/01 21:07
Delcath Systems makes key appointments
Delcath Systems (DCTH) appoints Gerard Michel as Chief Executive Officer, effective October 1, 2020. Mr. Michel will also serve as a member of Board He was the CFO and VP of Corporate Development at Vericel Corporation. In
Seekingalpha · 10/01 20:19
Encode Ideas, L.P. to Host Key Opinion Leader Conference Call with Dr. Jonathan Zager, Principal Investigator for Delcath System's Phase 3 FOCUS Study
Dover, Delaware--(Newsfile Corp. - September 28, 2020) - Encode Ideas, L.P. announces they will be hosting a conference call with Dr. Jonathan Zager, surgical oncologist at Moffitt Cancer Center and the principal investigator for the Phase 3 FOCUS study, on Wednesday, September 30 at 3:00 pm Eastern
Newsfile · 09/28 15:50
Delcath: Peek Of Early Data Of FOCUS Trial Shows Vastly Improved Safety Profile Of Chemosat
Safety data of early part of FOCUS trial have been publicly disseminated.Early data of FOCUS trial show a vastly improved safety profile of Chemosat.CEO confirmed there are no deaths reported in entire FOCUS trial.Overwhelming evidences suggest FOCUS trial will show a very favorable risk-benefit profile of Chemosat .
Seekingalpha · 09/25 22:14
Delcath Systems, Inc. to Participate in Upcoming Virtual Investor Conferences
NEW YORK, Sept. 10, 2020 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (NASDAQ: DCTH), an interventional oncology company focused on liver-directed treatment of rare primary and metastatic cancers, today announced management will participate in two upcoming virtual investor conferences: * H.C. Wainwright
GlobeNewswire · 09/10 14:00
Delcath Systems (DCTH) Investor Presentation - Slideshow
The following slide deck was published by Delcath Systems, Inc. in conjunction with this event.
Seekingalpha · 09/04 17:44
Delcath Systems Q2 EPS $(1.90) Misses $(1.69) Estimate, Sales $379.00K Miss $440.00K Estimate
Delcath Systems (NASDAQ:DCTH) reported quarterly losses of $(1.90) per share which missed the analyst consensus estimate of $(1.69) by 12.43 percent. This is a 2275 percent decrease over losses of $(0.08) per share from
Benzinga · 08/13 20:08
Delcath Systems EPS misses by $0.21, misses on revenue
Delcath Systems (DCTH): Q2 GAAP EPS of -$1.90 misses by $0.21.Revenue of $0.38M (-7.3% Y/Y) misses by $0.06M.Press Release
Seekingalpha · 08/13 20:02
More
Forecast
EPSBVPSCFPS
Actual (B USD)
Estimate (B USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of DCTH. Analyze the recent business situations of Delcath Systems Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 2 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average DCTH stock price target is 19.50 with a high estimate of 20.00 and a low estimate of 19.00.
EPS
Institutional Holdings
Institutions: 22
Institutional Holdings: 266.79K
% Owned: 6.78%
Shares Outstanding: 4.09M
TypeInstitutionsShares
Increased
0
0
New
14
266.79K
Decreased
0
0
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Medical Equipment, Supplies & Distribution
-0.25%
Healthcare Equipment & Supplies
+0.08%
Key Executives
Chairman/Independent Director
Roger Stoll
Chief Executive Officer/Director
Gerard Michel
Chief Operating Officer/Executive Vice President
John Purpura
Chief Accounting Officer
Christine Padula
Independent Director
Gilad Aharon
Independent Director
Elizabeth Czerepak
Independent Director
Steven Salamon
Independent Director
John Sylvester
  • Dividends
  • Splits
  • Insider Activity
No Data
  • All
  • Financials
  • Insiders
More
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About DCTH
Delcath Systems, Inc. is a late-stage clinical development company with early commercial activity in Europe focused on cancers of the liver. The Company is a specialty pharmaceutical and medical device company developing its product, Melphalan Hydrochloride for Injection for use with the Delcath Hepatic Delivery System (Melphalan/HDS). The Company's system delivers and filters melphalan hydrochloride, which is marketed as a device under the trade name Delcath Hepatic CHEMOSAT Delivery System for Melphalan (CHEMOSAT). The Company's focus is on the execution of the clinical development program (CDP) in ocular melanoma liver metastases (mOM), intrahepatic cholangiocarncinoma (ICC), hepatocellular carcinoma (HCC or primary liver) and other cancers that are metastatic to the liver.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Delcath Systems, Inc. stock information, including NASDAQ:DCTH real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, DCTH stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading DCTH stock methods without spending real money on the virtual paper trading platform.